Companies / Keros Therapeutics, Inc.

Keros Therapeutics, Inc.

Nasdaq: KROSCIK 1664710LEXINGTON, MA

Financials · FY2025

Revenue$244.06M
Net income$87.01M
Total debt—
Cash$257.61M
Diluted EPS$2.30
Shares outstanding19.8M

Ownership

19.8M shares outstanding · as of Jul 27, 2026
2.7%Insiders
Ownership
Insiders2.72%539,050
10%+ / strategic7.69%1,525,355
Institutions89.88%17,820,855
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Seehra JasbirCEOCHIEF EXECUTIVE OFFICER · Director
1.95%385,708
Cho EstherChief Legal Officer
0.20%39,755
Regnante KeithCHIEF FINANCIAL OFFICER
0.20%39,261
Lerner Lorena RaquelChief Scientific Officer
0.16%31,127
Bienaime Jean JacquesDirector
0.09%17,592
Newton Charles W.Director
0.07%13,215
Gray Mary AnnDirector
0.06%12,392

Institutional holders 173

View all →
HolderValue% of shares
Vanguard Group Inc$31.06M7.69%
BlackRock, Inc.$29.90M14.09%
Madison Avenue International LP$16.77M4.15%
Qube Research & Technologies Ltd$15.96M3.95%
Jacobs Levy Equity Management, Inc$15.65M3.88%
The Goldman Sachs Group, Inc.$12.02M2.98%
Citadel Advisors LLC$9.62M2.38%
Orbimed Advisors LLC$8.38M3.83%
Federated Hermes Inc$7.61M3.48%
Geode Capital Management, LLC$7.52M3.44%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 19, 2026Seehra Jasbir
CEO
SellCommon Stock$113.4K-7K
-1.79%
385,708
1.95% of shares
medium
Feb 18, 2026Cho Esther
Executive
SellCommon Stock$77.6K-5K
-10.66%
39,755
0.20% of shares
low
Feb 18, 2026Regnante Keith
Executive
SellCommon Stock$77.5K-5K
-10.77%
39,261
0.20% of shares
low
Feb 18, 2026Lerner Lorena Raquel
Executive
SellCommon Stock$63.3K-4K
-11.07%
31,127
0.16% of shares
low
Mar 9, 2026Bienaime Jean Jacques
Director
BuyCommon Stock$22.4K+2K
+36.70%
7,450
0.04% of shares
low
Apr 15, 2026Bienaime Jean Jacques
Director
BuyCommon Stock$11.7K+1K
+13.42%
8,450
0.04% of shares
low
May 15, 2026Bienaime Jean Jacques
Director
BuyCommon Stock$10.6K+1K
+11.83%
9,450
0.05% of shares
low
Jun 15, 2026Bienaime Jean Jacques
Director
BuyCommon Stock$10.2K+1K
+6.03%
17,592
0.09% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
D. E. Shaw & Co., L.P.Passive13G/A———
Vanguard Group IncPassive13G/A—1,525,355—
Vanguard Group IncPassive13G/A—0—
Tang Capital Management, LLCPassive13G/A—0—
ExodusPoint Capital Management, LPPassive13G/A———
Madison Avenue International LPPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
KROS——492327101—